SCHEDULE 13G/A: Bank of America Discloses 1.4% Passive Stake in Ventyx Biosciences

Bank of America Corporation has filed an amended Schedule 13G, disclosing a 1.4% beneficial ownership stake in Ventyx Biosciences, Inc. as of March 31, 2025.

Summary

• Bank of America Corporation, through its wholly-owned subsidiaries BofA Securities, Inc. and Bank of America N.A., has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Ventyx Biosciences, Inc.
• As of March 31, 2025, Bank of America Corporation beneficially owns 1,016,649 shares of Ventyx Biosciences, Inc. Common Stock.
• This ownership represents 1.4% of the total class of securities.
• The shares are held with shared voting power and shared dispositive power, with no sole voting or dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Ventyx Biosciences, Inc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership, which is a factual statement without explicit positive or negative operational implications for the issuer. The presence of a large institutional holder is generally viewed as neutral to slightly positive.

Positives

• The disclosure of a 1.4% stake by a major financial institution like Bank of America may signal institutional confidence in Ventyx Biosciences, Inc.
• The passive nature of the stake (13G filing) indicates that Bank of America is not seeking to influence or control the company, which can be viewed as a stable, non-activist investment.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of institutional ownership. While it doesn't provide specific industry insights, the presence of a major financial institution like Bank of America as a beneficial owner in a biotechnology company like Ventyx Biosciences is a common occurrence as part of their investment and trading activities.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Key Dates

Keywords

Ventyx Biosciences, Bank of America, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional ownership